Copyright
©The Author(s) 2021.
World J Crit Care Med. Sep 9, 2021; 10(5): 244-259
Published online Sep 9, 2021. doi: 10.5492/wjccm.v10.i5.244
Published online Sep 9, 2021. doi: 10.5492/wjccm.v10.i5.244
Table 3 Univariate Cox proportional hazards survival analysis of pharmacological and therapeutic interventions in coronavirus disease 2019 intensive care unit patients
B | SE | P value | HR | 95%CI | |
GC (all patients) | -0.84 | 0.16 | < 0.001 | 0.45 | 0.38-0.61 |
Vasopressors | 0.039 | 35 | 0.027 | 1.4 | 1.05-2.1 |
IV ascorbic acid | 0.1 | 0.15 | 0.49 | 1.1 | 0.91-1.5 |
Hydroxychloroquine | -0.58 | 0.36 | 0.1 | 0.56 | 0.27-1.14 |
Azithromycin | 0.25 | 28 | 0.39 | 1.3 | 0.72-2.3 |
Heparin therapeutic dose | 0.15 | 0.35 | 0.67 | 1.16 | 0.51-2.31 |
Heparin prophylaxis dose | -0.27 | 0.3 | 0.35 | 0.76 | 0.48-1.3 |
Convalescent plasma | 0.29 | 1 | 0.77 | 1.3 | 0.72-9.8 |
Remdesivir | 6 (3) | 0 | |||
Prone positioning | 0.36 | 0.52 | 0.44 | 1.43 | 0.51-1.4 |
Tocilizumab | -0.48 | 0.27 | 0.08 | 0.61 | 0.36-1.06 |
GC only | -0.75 | 0.21 | 0.001 | 0.47 | 0.18-0.41 |
GC + tocilizumab | -1.3 | 0.21 | <0.001 | 0.27 | 0.4-1.15 |
- Citation: Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World J Crit Care Med 2021; 10(5): 244-259
- URL: https://www.wjgnet.com/2220-3141/full/v10/i5/244.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v10.i5.244